(Q44194290)

30 November 2017

0 references

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients (English)

1 reference

relapsing-remitting multiple sclerosis

30 November 2017

main subject

0 references

author name string

R A Rudick

1

1 reference

30 November 2017

L Kappos

2

1 reference

30 November 2017

R Kinkel

3

1 reference

30 November 2017

M Clanet

4

1 reference

30 November 2017

J T Phillips

5

1 reference

30 November 2017

R M Herndon

6

1 reference

30 November 2017

A W Sandrock

7

1 reference

30 November 2017

F E Munschauer

8

1 reference

30 November 2017

publication date

21 October 2010

1 reference

Multiple Sclerosis Journal

30 November 2017

published in

1 reference

30 November 2017

volume

17

1 reference

30 November 2017

issue

3

1 reference

30 November 2017

page(s)

353-360

1 reference

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Multiple sclerosis: disability profile and quality of life in an Australian community cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Depressive symptoms in a treated multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Major depression in multiple sclerosis: a population-based perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510384605

21 January 2018

Identifiers

DOI

10.1177/1352458510384605

1 reference

release_3ibgihjfenditilyxoqqzi5jdm

30 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3ibgihjfenditilyxoqqzi5jdm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference